Seroconversion rate based on S glycoprotein levels measured previous, during, and after BsAbs treatment. (A) Seroconversion rate from the overall cohort through BsAbs treatment. (B) Seroconversion rate in patients who received anti-CD20 agent alone or in combination with chemoimmunotherapy >6 months ago and who were exposed to anti-CD20 agent alone or in combination with chemoimmunotherapy in the last 6 months. Posttreatment setting 1 corresponds to early posttreatment, <6 months after treatment with BsAbs. Posttreatment setting 2 corresponds to late posttreatment, >6 months after treatment with BsAbs.